Literature DB >> 3288845

Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo.

N Crona1, G Samsioe, U B Lindberg, G Silfverstolpe.   

Abstract

Org OD 14 (7 alpha,17 alpha-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) is a steroid possessing mixed hormonal activity, which in earlier studies has been shown to alleviate climacteric complaints and to prevent post-menopausal osteoporosis without affecting the endometrium. The effects of Org OD 14 on climacteric complaints were compared with those of oestradiol valerate (E2V) and placebo in a randomized, double-blind, cross-over study in 20 women who had been oophorectomized and hysterectomized 3-6 yr earlier as part of their treatment for cervical cancer. Each patient was treated orally for a total period of 18 wk, comprising 6 wk on each preparation. Capsules of identical appearance were given; these contained either 2.5 mg Org OD 14, 2 mg E2V or placebo. The patients' scores for symptoms and mood items on standardized rating scales were recorded at the end of each 6-wk treatment period (i.e. on days 43, 85 and 127). There were no differences between the effects of Org OD 14 and E2V on symptoms and mood items, while both compounds were more effective than placebo. Our findings confirmed that Org OD 14 is effective in ameliorating oestrogen deficiency symptoms in climacteric women.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288845     DOI: 10.1016/0378-5122(88)90095-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  3 in total

Review 1.  Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes.

Authors:  A H Maclennan; J L Broadbent; S Lester; V Moore
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

2.  Beneficial effect of tibolone on mood, cognition, well-being, and sexuality in menopausal women.

Authors:  Andrea Riccardo Genazzani; Nicola Pluchino; Francesca Bernardi; Manolo Centofanti; Michele Luisi
Journal:  Neuropsychiatr Dis Treat       Date:  2006-09       Impact factor: 2.570

3.  Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation.

Authors:  M A Karsdal; I Byrjalsen; D J Leeming; C Christiansen
Journal:  BMC Musculoskelet Disord       Date:  2008-11-18       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.